Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews · Headline outcomes only

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 62.5%Low 2 · 25%Moderate 0 · 0%High 1 · 12.5%

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether sarilumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.06 [0.86, 1.3]
9 studies · 3305 participants
Very low

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether clazakizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.91 [0.54, 1.55]
2 studies · 169 participants
Very low

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether olokizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.5 [0.55, 4.09]
1 study · 248 participants
Very low

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether siltuximab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.35 [0.54, 3.36]
1 study · 148 participants
Very low

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether levilimab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1 [0.26, 3.89]
1 study · 206 participants
Very low

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

Tociliuzumab leads to lower all‐cause mortality D28 compared with standard care/placebo (high certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.88 [0.81, 0.94]
18 studies · 7428 participants
High

All‐cause mortality D28

Canakinumab showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.75 [0.39, 1.42]
2 studies · 499 participants
Low

All‐cause mortality D28

Anakinra showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.69 [0.34, 1.39]
2 studies · 722 participants
Low